S2k-Guidelines – Cutaneous lymphomas (ICD10 C82 - C86): Update 2021

Guideline commissioned by the Working Group Dermatological Oncology (Arbeitsgemeinschaft Dermatologische Onkologie, ADO) of the German Cancer Society (Deutsche Krebsgesellschaft) and the German Dermatological Society (Deutsche Dermatologische Gesellschaft)

ADO Project Leader Guidelines: Prof. Dr. Stephan Grabbe, Mainz

Coordinator and corresponding author: Prof. Dr. Edgar Dippel

Edgar Dippel1, Chalid Assaf2, Jürgen C. Becker1, Michael von Bergwelt-Baildon3, Sophie Bernreiter1, Antonio Cozzio5, Hans T. Eich6, Khaled Elsayad6, Markus Follmann7, Stephan Grabbe8, Uwe Hillen9, Wolfram Klapper10, Claus-Detlev Klemke11, Carmen Loquai8, Frank Meiss12, Christina Mitteldorf13, Ulrike Wehkamp14, Dorothee Nashan15, Jan P. Nicolay16, Ilse Oschlies16, Max Schlaak5, René Stranzenbach17, Rose Moritz19, Christoph Stoll20, Tibor Vag21, Michael Weichert24, Marion Wobser22, Rudolf Stadler23

1 (i) Department of Dermatology, Hospital Ludwigshafen, Germany
2 (ii) Department of Dermatology and Venereology, Helios Hospital Krefeld, Germany
3 (iii) West German Tumor Center, University Hospital Essen, Germany
4 (iv) Department I of Internal Medicine, University Hospital Cologne, Germany
5 (v) Department of Dermatology, Venereology and Allergology, Cantor Hospital St. Gallen, Switzerland
6 (vi) Department of Radiation Therapy and Radio-Oncology, University Hospital Münster, Germany
7 (vii) German Cancer Society, Berlin, Germany
8 (viii) Department of Dermatology, University Hospital Mainz, Germany
9 (ix) Department of Dermatology, University Hospital Essen, Germany
10 (x) Institute of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
11 (xi) Department of Dermatology, Municipal Hospital of Karlsruhe, Academic Teaching Hospital for the University of Freiburg, Karlsruhe, Germany
12 (xii) Department of Dermatology and Venereology, University Hospital Freiburg, medica Faculty, Albert-Ludwigs University Freiburg, Germany
13 (xiii) Department of Dermatology, Venereology and Allergology, University Hospital Göttingen, Germany
14 (xiv) Department of Dermatology, Venereology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
15 (xv) Department of Dermatology, Dortmund Hospital GmbH, Dortmund, Germany
16 (xvi) Department of Dermatology, Venereology and Allergology, University Hospital Mannheim, Germany
17 (xvii) Charité – Universitätsmedizin Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany
18 (xviii) Department of Dermatology, Venereology and Allergology, University Hospital at Ruhr University Bochum, Germany
19 (xix) Department for Dermatology, University Hospital Halle, Germany
20 (xx) Rehabilitation Hospital, Herzoghöhe Bayreuth, Germany
21 (xxi) Department of Nuclear Medicine, Technical University of Munich, Germany
22 (xxii) Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Germany
23 (xxiii) Department of Dermatology, Venereology, Allergology, and Phlebology, Johannes Wesling University Hospital Minden, University Hospital at Ruhr University Bochum, Germany

© 2022 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. | JDDG | 1610-0379/2022/00
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1. General Remarks

1.1. Epidemiology, clinical presentation

**Statements**

Cutaneous lymphomas are a heterogeneous group of lymphoproliferative skin diseases with very variable clinical presentations and prognoses. Their incidence in Germany is estimated at about one per 100,000 inhabitants per year.

Cutaneous lymphomas (CL) are categorized as extranodal non-Hodgkin lymphomas, constituting the second most common form in this group (MALT lymphomas of the stomach are the most common extranodal form). Their incidence is estimated at one new diagnosis per 100,000 inhabitants per year in Germany [1–3]. Primary CL, by definition, present in the skin first, and at the time of diagnosis after staging is completed do not show any involvement of other organs. Secondary CL, on the other hand, are cutaneous manifestations of disseminated [4], primarily nodal lymphomas or leukemias. Primary CL comprise a large, clinically and histologically heterogeneous spectrum, with 73 % of CL categorized as cutaneous T-cell lymphomas (CTCL) and 22 % as cutaneous B-cell lymphomas (CBCL). There are other, rare forms of CL as well. Primary CL and nodal or extracutaneous lymphomas with the same cytomorphology actually differ greatly as to clinical presentation, but also prognosis and indicated treatments [5]. CL patients should therefore be treated in close collaboration between a specialized center and the primary physician. Cutaneous lymphomas are usually characterized by clonality of lymphocytes in the skin (with the exception of CD4+/CD56+ blastic plasmacytoid dendritic cell neoplasia). Their cytomorphological presentation is comparable to lymphomas in other locations. Based on the specific cutaneous microenvironment, clinical and histological presentation will vary. It is essential to differentiate primary CL from skin manifestations of extracutaneous lymphomas or leukemias.

2. Classification

**Statements**

Cutaneous lymphomas are classified according to the current WHO/EORTC classification [6–8], based on clinico-pathological (respectively, immunohistological and molecular biological) correlation. Cutaneous lymphomas are differentiated from extracutaneous (disseminated) lymphomas based on their primary manifestation in the skin. Thus, primary cutaneous lymphomas are defined as lymphomas that at the time of diagnosis after staging according to current guidelines are limited to the skin.

**Recommendations**

The primary examination must include an inspection of the whole skin, palpation of all lymph node stations, and a general physical examination.

Diagnosis of a cutaneous lymphoma shall be performed via biopsy with histological examination of a representative lesion.

Precise classification requires additional immunohistological investigations which should therefore be part of the diagnostic process.

If involvement of the blood is suspected, FACS analysis/flow cytometry is recommended, see Table 2.

Molecular biological clonality analysis should be performed. Consensus: 100 %, modified 2021

Imaging procedures, lymph node/bone marrow biopsy, and laboratory investigations to exclude extracutaneous involvement or secondary cutaneous lymphoma should be performed depending on the histological subtype of the lymphoma and the tumor stage according to Tables 2 and 3. Consensus: 100 %, modified 2021

Despite sometimes similar names (such as in marginal zone lymphoma and diffuse large B-cell lymphoma), cutaneous and extracutaneous/disseminated lymphomas differ as to their clinical as well as histopathological and molecular properties. One special feature in the classification of cutaneous lymphomas is the importance of clinical presentation for the final classification and prognosis. For example: A γ/δ-T-cell phenotype in itself is not sufficient for a classification as a cutaneous γ/δ-T-cell lymphoma. The classification also includes entities with unclear malignant potential (such as lymphomatoid papulosis, primary cutaneous CD4-positive small-medium T-cell lymphoproliferative disease). In analogy to systemic lymphomas, we differentiate between T-cell and B-cell neoplasias (Table 1); blastic plasmacytoid dendritic cell neoplasia is itemized as a hematological myeloic precursor neoplasia with typical primary manifestation in the skin. The new provisional WHO category of EBV-positive mucocutaneous ulcer should be mentioned as an Epstein-Barr virus (EBV)-associated skin disease, and must be differentiated from the rare EBV-positive diffuse large B-cell lymphoma. EBV-associated hydroa-vacciniforme-like lymphoproliferative disease is almost never seen in Germany. Consensus: 100 %, modified 2021
In the majority of skin lymphomas, clinical examination will already offer a provisional diagnosis, yet histological immunohistological, and molecular biological investigations are essential for confirmation. Apart from inspection of the whole skin, clinical examination of all lymph node stations is part of the primary examination.

4. Staging

Table 1  WHO-EORTC classification of cutaneous lymphomas.

| Cutaneous T-cell and NK-cell lymphomas | Cutaneous B-cell lymphomas |
|---------------------------------------|---------------------------|
| Mycosis fungoides (MF)                | Primary cutaneous follicle center lymphoma (PCFCL)** |
| – Folliculotrop MF                    | Primary cutaneous marginal zone B-cell lymphoma (PCMZL) |
| – Pagetoid reticulosis                | Primary cutaneous diffuse large B-cell lymphoma, leg type (PCBLT) |
| – Granulomatous slack skin            | **EBV-positive mucocutaneous ulcer** |
| Sézary syndrome (SS)*                 | (EBV-positive diffuse large B-cell lymphoma, not otherwise specified)*** |
| Adult T-cell leukemia/lymphoma (HTLV+)* | Primary cutaneous intravascular large B-cell lymphoma* |
| Primary cutaneous CD30+ lymphoproliferative diseases | **Hematological precursor neoplasms** |
| – Primary cutaneous anaplastic large cell lymphoma (PCALCL) | Blastic plasmacytoid dendritic cell neoplasm (BPDCN)* |
| – Lymphomatoid papulosis (LyP)        | |
| Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) | |
| Extranodal NK/T-cell lymphoma, nasal type* | |
| Primary cutaneous peripheral T-cell lymphoma, rare subtypes: | |
| – Primary cutaneous γ/δ-T-cell lymphoma | |
| – Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma | |
| – Primary cutaneous CD4+ small-medium T-cell lymphoproliferative disease | |
| – Primary cutaneous acral CD8+ T-cell lymphoma | |
| Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (NOS) | |

*Entities that manifest as primary cutaneous lymphomas but are often already disseminated/systemic at the time of diagnosis.
**Primary cutaneous follicle center lymphoma: Synonymous with German term “primär kutanes Keimzentrumslymphom (PCFCL)”
***The EBV-positive diffuse large B-cell lymphoma is not explicitly classified as a „cutaneous lymphoma“, but can present as isolated skin involvement and remains an important differential diagnosis to PCBLT and EBV-positive mucocutaneous ulceration.

Provisional entities are presented in italics

In the majority of skin lymphomas, clinical examination will already offer a provisional diagnosis, yet histological immunohistological, and molecular biological investigations are essential for confirmation. Apart from inspection of the whole skin, clinical examination of all lymph node stations is part of the primary examination.

4. Staging

**Recommendations**

Staging of CL should be performed according to the TNM classification proposed by the ISCL-EORTC/EORTC CL update B (blood) classification.

*Consensus: 100 %, modified 2021*

Staging of CTCL is performed using the TNM classification which also offers a certain prognostic factor. Especially in mycosis fungoides (MF), early stages (IA–IIA) usually have a very good prognosis with mean survival times of about 10 to 20 years. This T classification is not suitable for other types of lymphoma. The N category is also not the optimal solution in a clinical sense (for example N1/N2: clinically normal lymph nodes are usually not biopsied). For these reasons, the TNM classification for MF and Sézary syndrome (SS) has been revised and is now available as an updated TNMB classification, including changes regarding B staging (Tables 4, 5) [18, 19]. Future investigations and studies should utilize the revised classification.

The International Society of Cutaneous Lymphomas (ISCL) and the EORTC have proposed a dedicated classification of stages for CTCL, excluding MF and Sézary syndrome [20], which should find application in the future (Table 6).

It should be noted that, as opposed to the staging of MF/SS [18], the current “Non-MF/SS staging” does not offer any prognostic significance but at this point in time only reflects anatomical spreading. The position of clonality analysis in removed lymph nodes has been introduced for the first time [21, 22].
5. Treatment

### Statement

Treatment strategies are based on a precise diagnosis, previous treatments, and disease stage.

### Recommendations

- Treatment of MF shall be performed according to the recommendations in Table 7.  
  **Consensus: 100 %, modified 2021**
- Treatment of SS shall be performed according to the recommendations in Table 8.  
  **Consensus: 100 %, modified 2021**
- Treatment of CD30+-lymphoproliferative skin diseases shall be performed according to the recommendations in Table 9.  
  **Consensus: 100 %, modified 2021**

---

Treatment of cutaneous B-cell lymphomas shall be performed according to the recommendations in Table 10a, 10b.  
**Consensus: 100 %, modified 2021**

Since the CL represent a heterogeneous group of diseases, treatment strategies must be based on a precise diagnosis (entity-appropriate), prognosis, previous treatments, and tumor staging (stage-appropriate). There are only a handful of controlled studies that contain this essential information.

Treatment of CTCL must always be differentiated from treatment of CBCL. For the more common CTCL types, a stage-appropriate and basically restrictive treatment approach is recommended. In the early stages, topical treatments such as topical steroids, phototherapy, topical chemotherapy with cBCNU/chlormethine, topical bexarotene gel, or topical immunotherapy with imiquimod are preferred. In stages IA, IB, and IIA, phototherapy with narrow-band UVB (UVB...
Table 3  Staging studies in cutaneous lymphoma.*

| Cutaneous B-cell lymphomas | Instrumental diagnostics |
|---------------------------|-------------------------|
| Primary cutaneous follicle center lymphoma (PCFCL) | Full-body CT scan®, lymph node sonography [13], PET CT scan if indicated°° |
| Primary cutaneous marginal zone lymphoma (PCMZL) | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| Primary cutaneous diffuse large B-cell lymphoma, leg type (PCBLT) | Full-body CT scan®, lymph node sonography, MRI of the affected limb if indicated + PET CT scan if indicated°° |
| Primary cutaneous diffuse large B-cell lymphoma, other types | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| Primary cutaneous intravascular large B-cell lymphoma | Full-body CT scan®, lymph node sonography, skull MRI, PET CT scan if indicated°° |

| Cutaneous T-cell and NK-cell lymphomas | Instrumental diagnostics |
|---------------------------------------|-------------------------|
| Mycosis fungoides (MF) | Chest X-ray, abdominal and lymph node sonography |
| Mycosis fungoides variants | Chest X-ray, abdominal and lymph node sonography |
| – folliculotropic MF | Chest X-ray, abdominal and lymph node sonography |
| – pagetoid reticulosis | Chest X-ray, abdominal and lymph node sonography |
| – granulomatous slack skin | Chest X-ray, abdominal and lymph node sonography |
| Mycosis fungoides from stage IIb onwards | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° [14–17] |
| Sézary syndrome (SS) | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| Adult T-cell leukemia/lymphoma (HTLV⁺) | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| Primary cutaneous CD3⁺ lymphoproliferative diseases | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| – primary cutaneous anaplastic large cell lymphoma (PCALCL) | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| – lymphomatoid papulosis (LyP) | Chest X-ray, lymph node sonography |
| Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| Extranodal NK/T-cell lymphoma, nasal type | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| Primary cutaneous peripheral T-cell lymphoma, rare subtypes | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| – primary cutaneous γ/δ-T-cell lymphoma | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| – primary cutaneous CD8⁺ aggressive epidermotropic cytotoxic T-cell lymphoma (provisional) | Full-body CT scan®, lymph node sonography, PET CT scan if indicated°° |
| – Primary cutaneous CD4⁺ small-medium T-cell lymphoproliferative disease (provisional) | Chest X-ray, abdominal and lymph node sonography (in cases of clinical uncertainty, staging may be performed via sectional imaging) |
| – Primary cutaneous acral CD8⁺ T-cell lymphoma (provisional) | Chest X-ray, abdominal and lymph node sonography (in cases of clinical uncertainty, staging may be performed via sectional imaging) |
| – Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (NOS) | Chest X-ray, abdominal and lymph node sonography (in cases of clinical uncertainty, staging may be performed via sectional imaging) |
| Blastic plasmacytoid dendritic cell neoplasia (BPDCN) | Full-body CT scan®, cMRI, (lymph node sonography), PET CT if indicated°°, bone marrow biopsy, CSF analysis if indicated°° |

*The recommendations apply for first-time staging. Staging examinations adapted to the individual patient situation should be performed after therapy, in case of disease progression, and for aggressive types of lymphoma.

°Full-body CT scans: neck, thorax, abdomen, pelvis using intravenous contrast agents

°°Retrospective examinations with small number of cases predominantly showed a significant superiority of 18F-FDG PET/CT scans compared to conventional imaging methods, especially in the detection of lymph node and organ manifestations [14–17]. Nevertheless, larger prospective studies with sufficient evidence are currently lacking. In general, the costs for PET-CT-examinations for this indication are not covered by the statutory health insurances.
311 nm) or PUVA (psoralen plus UVA, e.g. oral PUVA, bath-, creme- or shower PUVA) may be performed. PUVA should be utilized primarily for patients with thick plaques or folliculotropenic MF. Both PUVA and UVB 311 nm are appropriate for treating erythrodermic MF [23].

For localized CTCL, radiotherapy with a total dose of typically ≥ 30 Gy in single doses of 2 Gy will lead to sustained local disease control in 90–100 % of cases [24]. Low-dose palliative radiotherapy (4–8 Gy) for cutaneous B-cell and T-cell lymphoma is an alternative approach [25]. New studies show that radiotherapy with 4 Gy can adequately control the lesions of indolent cutaneous BCL [26]. For CTCL, use of 8 Gy in one or two fractions led to complete remission in ≥ 92 % of patients [27]. In stage IIB, this approach can be combined interferon-PUVA or bexarotene-PUVA or bexarotene alone, to achieve sustained disease control in the early stages. Other multimodal therapeutic combinations are feasible as well. In cases of low tumor burden, a combination of topical or systemic treatment with low dose radiation has proven successful, especially due to the reassuring side-effect profile. In general, total skin electron beam treatment at conventional doses (30–36 Gy) is a feasible option in patients with cutaneous T-cell lymphoma; however, this is associated with higher-grade skin toxicity [28, 29]. Newer studies show that low-dose total skin electron beam treatment at 10–12 Gy over a period of 2–3 weeks can be considered a reliable and safe treatment option to achieve short-term success with a lower toxicity profile [28, 30, 31]. Subsequently, adjuvant topical or systemic treatment should be considered to maintain remission (maintenance therapy) [32, 33].

Systemic treatments, such as a combination of PUVA with retinoids or recombinant interferon-alpha, are the obvious choice for advanced stages (Table 7) [34–36]. Bexarotene, another systemic medication, can also be recommended [37–40].

Table 4 ISCL/EORTC revision of classification and staging of mycosis fungoides and Sézary syndrome/EORTC CL update B classification.

| Category | Definition |
|----------|------------|
| **T: Skin** | |
| **T1** | Macules, papules, and plaques ≤ 10 % of skin surface  
a) Macules  
b) Plaques ± macules |
| **T2** | Macules, papules, and plaques ≥ 10 % of skin surface  
a) Macules  
b) Plaques ± macules |
| **T3** | One or more tumors (≥ 1 cm) |
| **T4** | Erythroderma (≥ 80 % of skin surface) |
| **N: Lymph nodes** | |
| No | No palpable lymph nodes |
| N1 | Palpable lymph nodes; no histological evidence for CTCL (NCILN<sub>n</sub>)  
a) clone negative  
b) clone positive |
| N2 | Palpable lymph nodes; histological evidence for scant T-cell lymphoma infiltrations (NCILN<sub>n</sub>)  
a) clone negative  
b) clone positive |
| N3 | Palpable lymph nodes; histological evidence for extensive T-cell lymphoma infiltrations (NCILN<sub>n</sub>), clone positive or negative |
| Nx | Clinically abnormal lymph nodes, no histological confirmation |
| **B: Peripheral blood**<sup>+</sup> | |
| B0 | < 250 CD<sub>4</sub><sup>+</sup>CD<sub>7</sub><sup>-</sup> or CD<sub>4</sub><sup>+</sup>CD<sub>26</sub><sup>-</sup> T lymphocytes/μl [19] |
| B1 | 250 bis <1000 CD<sub>4</sub><sup>+</sup>CD<sub>7</sub><sup>-</sup> or CD<sub>4</sub><sup>+</sup>CD<sub>26</sub><sup>-</sup> T lymphocytes/μl [19] |
| B2 | ≥ 1000 CD<sub>4</sub><sup>+</sup>CD<sub>7</sub><sup>-</sup> or CD<sub>4</sub><sup>+</sup>CD<sub>26</sub><sup>-</sup> T lymphocytes/μl with identical clonal T-cell receptor gene rearrangement of the skin clone [19] |
| **M: Visceral organs** | |
| Mo | No involvement of visceral organs |
| M1 | Histologically confirmed visceral involvement with organ specification |

Table 5 Clinical staging for mycosis fungoides and Sézary syndrome.

| ISCL/EORTC 2007 | T | N | M | B |
|-----------------|---|---|---|---|
| IA | 1 | 0 | 0 | 0.1 |
| IB | 2 | 0 | 0 | 0.1 |
| IIA | 1–2 | 1–2 | 0 | 0.1 |
| IIB | 3 | 0–2 | 0 | 0.1 |
| IIIA | 4 | 0–2 | 0 | 0 |
| IIIB | 4 | 0–2 | 0 | 1 |
| IVA | 1–4 | 0–2 | 0 | 2 |
| IVA | 1–4 | 3 | 0 | 0–2 |
| IVB | 1–4 | 0–3 | 1 | 0–2 |
Use of interferon-alpha is, however, limited by the fact that the approved preparation Roferon has been withdrawn and is no longer available for treating patients with cutaneous lymphomas. There are no generic alternatives. There are some case reports in the literature of patients successfully treated with pegylated interferons (PEG-IFN) off label. Two larger studies on PEG-IFN have been published. PEG-IFNα-2a was used in CTCL patients (n = 13) at doses of 180 μg/week and 270 or 360 μg/week, respectively. The medication was effective and well tolerated, with no significant differences in the efficacy of lower or higher doses [41]. In a total of 17 patients, PEG-IFNα-2b (1.5 μg/kg body weight [BW]/weeks) plus PUVA (n = 9) was compared with the former standard treatment of IFNα-2a (9 MIU 3x/week) plus PUVA (n = 8). This study showed excellent efficacy for PEG-IFNα-2b, although side effects such as liver toxicity and myelosuppression were observed more frequently in comparison, highlighting the need for special attention in such cases and the need of starting with a moderate dose e.g. 180 μg of PEG-IFNα-2b [42].

The antibody conjugate brentuximab vedotin is another treatment option for advanced CD-30-positive MF (tumor stage). In 2019, the monoclonal anti-CCR4 antibody mogamulizumab was approved as a systemic second-line treatment for treatment-refractive and advanced MF and SS. It is especially effective for blood involvement [43]. Alternatively, there are two histone deacetylase inhibitors: vorinostat [44] (approved in the USA in 2006) and romidepsin [45] (approved 2011, USA), as well as the antimitabole talaprevir [46] (approved 2011, USA). The fusion toxin denileukin diftitox is currently no longer available [47]. Monochemotherapies, for example with gemcitabine which may be used in low-dose [48, 49] or doxorubicin [50], are preferred over polychemotherapies due to a more favorable side effect profile. The latter can induce massive immunosuppression without any improvement in survival [51]. The stage-adapted treatment recommendations are still based on the TNM classification published by the MF Cooperative Group in 1979. In the future, treatment recommendations will be based on the revised TNM classification [18].

Extracorporeal photopheresis is effective for SS, with few side effects. This can also be combined with interferon-alpha, PUVA, topical corticosteroids, or bexarotene (Table 8) [63].

In late stages, palliative chemotherapy is also an option (Table 8). It should be noted, however, that this has no proven effect on survival and may result in further immunosuppression with more frequent infectious complications.

Second-choice treatments include bexarotene (preferably in combination with PUVA and ECP), low-dose methotrexate (MTX; preferably in combination with PUVA and ECP), or total skin electron beam treatment. Doxorubicin or gemcitabine can be considered for debulking in advanced staged of Sézary syndrome. Alemtuzumab should be preferably used at low doses since high doses are associated with a high rate of infection. Allogenic stem cell transplants may be indicated for selected patients. If the tumor cells show CD30 expression, brentuximab vedotin may be used as an alternative [56]. Since 2019, the monoclonal anti-CCR4 antibody mogamulizumab has been available as a systemic second-line treatment for SS (after at least one previous systemic treatment), and is generally well tolerated [43]. Several HDAC inhibitors (vorinostat, romidepsin) are approved for treating SS outside Europe.

| Category | Definition |
|----------|------------|
| T: Skin  |            |
| T1       | Solitary skin lesions |
|          | a) solitary lesion, diameter < 5 cm |
|          | b) solitary lesion, diameter > 5 cm |
| T2       | Regional skin involvement with multiple skin lesions, limited to one body region or two adjacent regions |
|          | a) Involvement limited to a diameter of < 15 cm |
|          | b) Involvement diameter between 15 and 30 cm |
|          | c) Involvement diameter > 30 cm |
| T3       | Generalized skin involvement |
|          | a) multiple skin lesions distributed over two non-adjacent body regions |
|          | b) multiple skin lesions > 3 body regions |
| N: Lymph nodes |            |
| N0       | No clinical or pathological involvement of lymph nodes |
| N1       | Involvement of one peripheral LN region representing the draining area of current or previous skin involvements |
| N2       | Involvement of 2 or more peripheral LN regions, or involvement of other LN regions not located in the draining area of skin involvement |
| N3       | Involvement of central lymph nodes |
| M: Visceral organs |            |
| M0       | No evidence of extracutaneous involvement |
| M1       | Extracutaneous organ involvement, excluding lymph nodes |
Table 7  Therapy recommendations for MF and MF special forms.

| Stages | Recommended treatment First line* | Recommended treatment Second line* | Comment |
|--------|-----------------------------------|------------------------------------|---------|
| I A    | – topical steroids class III–IV  | – topical BCNU/carmustine**        |         |
|        | – PUVA                            | – Bexarotene gel**                 |         |
|        | – UVB-311 nm                      | – Topical immune therapy (such as  |         |
|        | – Chlormethine hydrochloride     |         |         |
|        | 0.02 % Gel°°                      |         |         |
|        | – topical BCNU/carmustine**      | – PUVA + IFNα                      |         |
|        | – PUVA + bexarotene               | – Bexarotene                        |         |
|        | – Bexarotene                      | – Low-dose methotrexate (MTX)      |         |
|        | – Acitretin***                    | – Topical radiotherapy             |         |
|        | – Low-dosed total skin electron   | – Low-dosed total skin electron    |         |
|        | beam treatment (8–12 Gy) (12 Gy)  |         |         |
|        | – Brentuximab vedotin+**          |         |         |
|        | – Mogamulizumab++ [42]            |         |         |
|        | – Brentuximab vedotin** [54, 55]  |         |         |
|        | Unilesional MF, pagetoid reticulosis | – PUVA/UVB-311 nm, if indicated  |         |
|        | – Topical radiotherapy (RT)       | – PUVA + IFNα                      |         |
|        | (30–36 Gy or 2 × 4 Gy)            | – PUVA + bexarotene                |         |
|        | – PUVA                            | – Bexarotene                        |         |
|        | – UVB-311 nm                      | – Low-dose MTX                     |         |
|        | – see stage I A                   | – Topical radiotherapy for tumors  |         |
|        | – PUVA + IFNα                     | – Gemcitabine                      |         |
|        | – PUVA + bexarotene               | – Doxorubicin*                     |         |
|        | – Low-dosed MTX                   | – Low-dosed total skin electron    |         |
|        | – Brentuximab vedotin+ [55, 56]   |         |         |
|        | – Mogamulizumab+++ [43]           |         |         |
|        | – If indicated: allogenic stem cell | transplant ++++ [57, 58]         |         |
|        | – IFNα is currently only available | as a pegylated formulation.       |         |
|        | – IFNα is currently only available | as a pegylated formulation.       |         |
|        | as a pegylated formulation.       | as a pegylated formulation.       |         |
| II B   | – PUVA/UVB-311 nm, if indicated  | – As for stage II B                |         |
|        | combined with IFNα, bexarotene    | – Alemtuzumab [60]                 |         |
|        | – Photopheresis, if indicated     | – Chlorambucil/steroid (Winkelmann |         |
|        | combined with IFNα [59], MTX, bex |         |         |
|        | – RT for tumors                   | – program or Knospe program) [61] |         |
|        | – RT for tumors                   | – Alemtuzumab: Low-dose            |         |
|        | – see stage II B                  | therapy only for patients with    |         |
|        | – see stage II B                  | cutaneous T-cell lymphoma and     |         |
|        | – Alemtuzumab [60]                | exclusive involvement of           |         |
|        | – Chlorambucil/steroid (Winkelmann|         |         |
|        | – program or Knospe program) [61] | – possibly: maintenance therapy   |         |
|        | – RT for tumors                   | with PUVA+IFNα/bexarotene/MTX      |         |
|        | – see stage II B                  | once remission has been achieved.  |         |
| IV A   | – PUVA, if indicated combined     | – See stage II B                   |         |
|        | with IFNα [56], bexarotene, RT    | – See stage II B                   |         |
|        | for tumors                        | – See stage II B                   |         |
| IV B   | – PUVA, if indicated combined     | – See stage II B                   |         |
|        | with IFNα [56], bexarotene, RT    | – See stage II B                   |         |
|        | for tumors                        | – See stage II B                   |         |
|        | – RT for tumors                   | – CHOP/CHOP-like-polychemotherapy  |         |
|        | – RT for tumors                   | – Alemtuzumab                      |         |
|        | – see stage II B                  | – Cladribine, Fludarabine,         |         |
|        | – see stage II B                  | – Cyclophosphamide                 |         |
|        | – CHOP/CHOP-like-polychemotherapy | – Alemtuzumab                      |         |
|        | – RT for tumors                   | – Cladribine, Fludarabine,         |         |
|        | – CHOP/CHOP-like-polychemotherapy | – Cyclophosphamide                 |         |
|        | – RT for tumors                   | – Alemtuzumab                      |         |
|        | – RT for tumors                   | – Cladribine, Fludarabine,         |         |
|        | – RT for tumors                   | – Cyclophosphamide                 |         |
| IV B   | – PUVA, if indicated combined     | – See stage II B                   |         |
|        | with IFNα [56], bexarotene, RT    | – See stage II B                   |         |
|        | for tumors                        | – See stage II B                   |         |
|        | – RT for tumors                   | – CHOP/CHOP-like-polychemotherapy  |         |
|        | – RT for tumors                   | – Alemtuzumab                      |         |
|        | – RT for tumors                   | – Cladribine, Fludarabine,         |         |
|        | – RT for tumors                   | – Cyclophosphamide                 |         |

*Individual multimodal therapy options are prioritized.

**Topical chlormethinhydrochlorid gel can be used as a combination therapy in all stages.

*The order within a column does not imply a valuation.

**Not authorized in Germany.

***Acitretin: possible as an alternative in cases where bexarotene is contraindicated.

****Erythrodermic MF: RT: Superficial x-rays or electrons; photons, where appropriate.

*pPegylated liposomal doxorubicin is generally not prescribable at the expense of the statutory health insurance funds. For details on prescribability, please refer to the GBA [62].

++Off-label use.

+++Mogamulizumab preferably in cases of MF with blood involvement and Sézary syndrome.

++++Allogeneic stem cell transplantation: reduced conditioning, preferably through clinical trials; “clinical option” only in case of matching donor.
CBCL without further manifestations offer a much better prognosis than nodal B-cell lymphomas. Thus, in many cases topical treatment is sufficient. Surgical removal or radiotherapy are feasible options. In individual cases, interferon treatment may result in complete remission. Polychemotherapy is only indicated for extracutaneous manifestations.

For most rare CL, there are no large studies and thus no evidence-based treatment recommendations or approved therapeutic options.

For the treatment of indolent CTCL, acral CD8+ T-cell lymphoproliferation, and CD4+ small-/medium size T-cell lymphoproliferative disease, excision or topical treatment are sufficient.

For blastic plasmacytoid dendritic cell neoplasia (BPD-CN) in a CR1 situation (complete remission directly after the first chemotherapy course), the primary recommendation is an allogenic or autologous bone cell transplant [69, 70]. Hematooncologists must therefore be consulted early for optimal treatment planning. Tagraxofusp was approved in November 2020 as a first-line monotherapy for adult patients with BPDCN. This compound consists of a shortened diphteria toxin (DT) fusion protein linked with recombinant human interleukin-3 (IL-3) to target CD123-expressing cells. Tagraxofusp irreversibly inhibits protein synthesis of target cells by inactivating elongation factor 2 (EF2). This induces apoptosis (cell death) [71].

For subcutaneous panniculitis-like T-cell lymphomas without evidence of hemophagocytic syndrome (HPS),

| Table 8 | Therapy recommendations for Sézary syndrome.° |
| --- | --- |
| **Treatment options:** | **Treatment options:** |
| First choice | Second choice |
| Extracorporeal photo- pheresis (ECP), if indicated combined with PUVA, IFNα, and/or bexarotene | Mogamulizumab [43] |
| PUVA combined with IFNα and/or bexarotene | Chlorambucil/steroid (Win- kelmann program) |

**The order within a column does not imply a valuation.**

*Pegylated liposomal doxorubicin is generally not prescribable at the expense of the statutory health insurance funds. For details on prescribability, please refer to the GBA [62].

**Off-label use.

***For selected patients, allogeneic stem cell transplantation may be indicated.

Table 9 Therapy recommendations for CD 30+ lymphoproliferative disorders of the skin.

| Extent | First choice | Second choice |
| --- | --- | --- |
| Solitary or localized lesions | Excision and/or radiotherapy (PCALCL) [65, 66] | Observation (LyP) |
| Multifocal lesions relapsing, possibly with spontaneous remission | Observation (LyP) | Low-dose methotrexate |
| | PUVA/UVB1 (LyP) | (pegylated) IFNα |
| | Brentuximab vedotin | Bexarotene |
| | | Gemcitabine |

°The order within a column does not imply a valuation.

**Pegylated liposomal doxorubicin is generally not prescribable at the expense of the statutory health insurance funds. For details on prescribability, please refer to the GBA [62].

**Off-label use.

***For selected patients, allogeneic stem cell transplantation may be indicated.

Table 10a Therapy recommendations for low-malignant primary cutaneous B-cell lymphomas (follicular center lymphoma, marginal zone lymphoma).

| Extent | First choice | Second choice |
| --- | --- | --- |
| Solitary lesions | “Watch & wait”++ | Antibiotics (if associated with borrelia) |
| | | Excision and/or radiotherapy |
| | | Intralesional rituximab* |
| Multiple lesions | Antibiotics (if associated with borrelia) | Bendamustine, combined with i.v. rituximab** |
| | Radiotherapy | if indicated |
| | Intralesional rituximab* | Doxorubicin or gemcitabine, combined with rituximab if indicated [67] |
| | i.v. rituximab | |

*Off-label use.

**Analogous to the experience in systemic indolent B-cell lymphomas, bendamustine may be considered as an alternative.

++Watch & wait: not in case of follicular lymphoma of the lower leg.
prednisolone monotherapy is recommended [72], if indicated also in combination with ciclosporin or MTX [73–75].

6. Innovative future treatments

Statement
As with traditional treatments, innovative therapies must consider the precise diagnosis, comorbidities, previous treatments, and tumor stage. Their use has been documented in individual case reports or case series, and occasionally also controlled clinical multicenter trials [56, 76].

Recommendation
Due to the limited number of newly approved therapies, treatment of primary cutaneous lymphomas with innovative forms of therapy should preferably be performed in the context of clinical trials (www.clinicaltrials.gov). In the course of improved decoding of the molecular bases and differentiated immune phenotyping, individualized treatment with targeted drugs may also become possible off-label, outside of clinical trials. For a better understanding of individual responses, data should also be collected in registries (such as ADOReg, PROCLIPI).

Consensus: 100 %, modified 2021

Alternative experimental topical treatments

In cutaneous T-cell lymphomas, activating phospholipase Cγ mutations with constitutive activation of the T-cell receptor-dependent NFAT pathway represent the rationale for using topical calcineurin inhibitors for MF [77]. Analogously, inhibition of deregulated toll-like receptor signaling is observed in MF [78]. Immunomodulators such as imiquimod and resiquimod could induce local remission and may thus offer a potential corticoid-free alternative in the future [52, 53]. To date, however, use of these topical treatments has only been studied in individual case reports/case series, and in the case of resiquimod in one small monocentric clinical trial (NCT01676831). Another innovative therapeutic option is intralesional application of a CD47 antibody which regulates innate immunity for tumor control.

Alternative experimental systemic therapies

Numerous new, promising systemic therapies for CL have become available in clinical studies or off-label for systemic hematological B-cell and T-cell neoplasias.

An innovative antibody targeting the surface molecule KIR3DL2 has shown promising preliminary clinical data. Drugs that interfere with epigenetic mechanisms, such as histone deacetylase inhibitors (vorinostat, romidepsin, belinostat, and panobinostat, all currently approved in the USA), or immunomodulatory compounds such as lenalidomide, constitute alternative or additive therapeutic options for MF, SS, and peripheral T-cell lymphomas [79–81]. HDAC inhibitors are not currently available in Germany outside of clinical studies (resminostat, NCT02953301).

Proteasome inhibitors such as bortezomib, which interfere with the aberrantly activated NFκB pathway, may show clinical effects in MF or peripheral T-cell lymphomas in combination with conventional therapeutic options in the absence of other alternatives [82, 83]. In view of activating mutations, inhibition of the JAK/STAT pathway may also constitute an innovative therapeutic option in the future for MF and peripheral T-cell lymphomas, in analogy to its use in systemic peripheral T-cell lymphomas [84, 85].

Innovative compounds for primary CBCL include, on the one hand, more effective and/or better tolerated CD20 antibodies such as obinutuzumab or ofatumumab, which have already been approved for treating systemic B-cell lymphomas [86, 87], or (additive) immunoregulatory compounds such as lenalidomide [88, 89]. Pixantrone, an alkylating substance with reduced cardiotoxicity compared with doxorubicin, appears especially attractive for elderly patients with primary cutaneous large B-cell lymphoma in view of commonly found (cardiac) comorbidities [90, 91].

For cutaneous B-cell lymphomas as well, future decoding of deregulated pathways will facilitate the use of targeted medications such as Bruton’s kinase inhibitors (ibrutinib) or phosphoinositide 3-kinase (PI3K) inhibitors (idelalisib). Some of these have already been approved for systemic B-cell non-Hodgkin lymphoma and are thus available off-label also for cutaneous B-cell lymphomas, especially treatment-refractive large B-cell lymphoma, leg type (PCBLT) [92–94]. Another promising candidate for this indication is the fusion protein polatuzumab, which has already been approved for systemic diffuse large B-cell lymphoma in combination with rituximab and bendamustine [95].
7. Maintenance therapy

**Statement**

Data from clinical studies on maintenance therapy in CL are insufficient.

*Verified 2021*

Once complete remission or an earlier stage has been achieved in advanced lymphomas, non-cytotoxic treatment recommendations in this guideline should be employed [96].

8. Supportive treatment

Pruritus, a common and distressing symptom in CL, impairs patients’ quality of life at any stage of the disease [97]. It is frequently permanent and worsens toward the end of the day and with warmer temperatures, sometimes also upon contact with water. Sleep is often disturbed. Basic treatment, topical steroids, and oral antihistamines can only rarely achieve improvement [98]. Apart from specific treatment of the cutaneous lymphoma, symptomatic treatment of
pruritus therefore deserves high priority in the therapeutic concept.

To date, the current DDG (Deutsche Dermatologische Gesellschaft, German Dermatological Society) guideline on treatment of chronic pruritus offers the following systemic treatment options for patients with cutaneous lymphomas [99]:

### Table 11c  Follow-up recommendations for primary cutaneous large cell anaplastic T-cell lymphoma after the onset of complete remission.

|                              | Cutaneous | Extracutaneous |
|------------------------------|-----------|----------------|
| **Medical history and physical examination** |           |                |
| Year 1–2                     | Every 3–6 months | Every 3 months |
| Year 3–5                     | Every 6 months  | Every 6 months |
| Year 6 onwards               | Yearly    | Yearly         |
| **Lymph node sonography**    |           |                |
| Year 1–2                     | Every 6 months  | Every 3 months |
| Year 3–5                     | Every 6 months  | Every 6 months |
| Year 6 onwards               | Yearly    | Yearly         |
| **Other imaging (CT, PET-CT if indicated)** | Individually |                |

In addition to systemic medications, basic soothing skin care is also useful. Because of similarity to atopic eczema in the impairment of the skin barrier function [104], this can be applied in analogy to atopic eczema. It can also be used in addition to specific topical treatments. Twice-daily use of hydrophilic moisturizers on affected skin and lipophilic moisturizer for non-affected, dry skin is recommended. Ingredients such as urea, glycerin and sodium chloride, or local anesthetics such as menthol, benzocaine, camphor, or similar compounds may alleviate pruritus [99, 105–107].

Advanced stages of cutaneous lymphomas present a special challenge. These include disfiguring disease manifestations affecting body regions that cannot be covered, like in erythroderma, extensive infiltration of the facial skin, or large ulcerating tumors with an unpleasant smell. Quality of life near the end of patients’ lives will be greatly impaired, and the burden for both patients and caregivers has been described as traumatic [108–111].

At the end of life, optimal pain relief, wound care, general measures such as mitigation of odors, as well as professional nursing, palliative, and psycho-oncological support of patients and their caregivers will be key. The reader is referred to the guideline on palliative and supportive care, which offers valuable recommendations on pain relief, palliative wound care, and interaction with patients and caregivers in the dying phase [112].

### 9. Follow-up

#### Statement

Data from clinical trials on follow-up for CL patients is insufficient.

*Consensus: 100 %, verified 2021*

Recommendations for follow-up for patients with CL mainly refer to patients with complete remission (CR). Patients with stable disease (SD) or partial remission (PR) are more or less continuously undergoing treatment, so the working group on guidelines (cutaneous lymphomas) has decided to focus on patients with CR, while acknowledging that the database on follow-up in this field is insufficient [113–118]).

The following goals for follow-up in CL patients were identified:
10. Psychooncological aspects and health-related quality of life

**Recommendation**

As suggested by the comprehensive S3 guideline “Psychooncological diagnostics, counseling, and treatment of adult cancer patients (Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten [4]) psychological burden and health-related quality of life (screening) should also be investigated in patients with cutaneous lymphomas, if possible including family and social environment.

**Consensus: 100 %, verified 2021**

Psychooncology includes all clinical and scientific endeavors that evaluate the influence of psychological and social factors in the development and clinical course of cancerous diseases, as well as the individual, familial, and social processes of coping with the disease. It also comprises the systematic utilization of this knowledge for prevention, early detection, diagnostics, treatment, follow-up, and rehabilitation [119]. Its most important goal is to recognize strain on patients and caregivers as early as possible and initiate appropriate treatment [120, 121]. Investigation of health-related quality of life (HRQL) is now standard in patients with advanced cancer, comprising physical, emotional, cognitive, social, spiritual, and behavioral aspects of functionality and well-being. There are currently no specific instruments for evaluating HRQL in patients with cutaneous lymphomas, but these are being developed [122].

The impact of cutaneous lymphomas on the various psychosocial dimensions as well as quality of life, and consequently on the need for appropriate support, have not been systematically investigated until now [108]. Individual studies show significantly reduced quality of life in patients with cutaneous lymphomas, with fatigue, pain, and disturbed sleep emerging as the main problems [111, 123]. A survey among members of the mycosis fungoides foundation in the USA confirms that fatigue and disturbed sleep are the most common complaints in cutaneous lymphoma patients [124]. A study on the impact of pruritus on CL patients’ quality of life confirmed a strong correlation between intensity of pruritus and impaired quality of life [125]. In an international observational study (PROCLIPi), female sex and alopecia were identified as independent predictors for inferior global health-related quality of life [126]. Increased values for anxiety and depression were observed especially in those patients treated with interferon and steroids, as well as specific drug-related toxicities observed in the context of treatment studies [111].

Apart from the impact on patients’ psychosocial dimensions and quality of life, the disease also displays clear effects on the familial environment [109, 127].

Recent studies have shown that low-dose total skin electron beam treatment (TSEBT) as well as immunotherapies (such as brentuximab vedotin, mogamulizumab, or anti-KIR3DL2 antibodies) can improve symptoms and various dimensions of health-related quality of life in patients with MF or SS [32, 128–132].

In general, improvement of treatment options with better tumor control and reduced toxicity also result in improved quality of life.

11. Palliative Care

Palliative care encompasses holistic care for patients with advanced disease, aimed at symptom control and care for patients with progressive, incurable, and terminal disease. The WHO describes palliative care as problem-oriented management in life-threatening disease, involving both patients and caregivers. The necessity of active treatment for physical, psychological, social, and spiritual problems is determined by the patient’s needs [112, 133]. Thus, palliative care can improve quality of life, symptoms, and conditions of care for both patients and their families [108]. Although evidence is limited, there is a desire among family members for better information, improved care, and the ability to cope with disease [127]. Recommendations can be found in the S3 guideline “Palliative care for patients with incurable cancer” (Palliativmedizin für Patienten mit einer nicht heilbaren Krebskrankung) [112].

A systematic review investigated the documentation of physical and psychological requirements as well as quality of life in patients with cutaneous lymphomas and their families: 18 studies showed intense symptomatic and emotional strain on patients [108]. Pruritus is the most troublesome symptom, followed by pain with potential involvement of psychological, functional, and emotional distress [109]. There is evidence for an association between disease severity and progression. The correlation of symptom improvement with treatment success cannot be uniformly evaluated. There are
some indications of special features in the palliative evaluation of patients with cutaneous lymphoma within the overall cohort of palliative patients [134].

Further development of dedicated services/interventions requires a detailed understanding of the needs of patients with cutaneous lymphomas and their families or caregivers.

Acknowledgement

The coordinating team would like to thank the following individuals: Dr. Markus Follmann for his tireless and expert advice during the whole project. Dipl. soz. Th. Langer for his support in the search for literature. Also, all elected officials, experts, and members of working groups who contributed to the last guideline on cutaneous lymphomas: (Update 2012) Reinhard Dummer, Dirk Vordermark, Martin Dreyling, Jürgen Dunst, Rolf-Dieter Kortmann, Bernhard Wörmann, Lutz Tischendorf and Wolfram Sterry; (Update 2016) Marc Beyer, Dominik Mestel, Cristina Lamos.

Correspondence to

Prof. Dr. med. Edgar Dippel
Hautklinik Ludwigshafen
Bremserstraße 79
67063 Ludwigshafen am Rhein
Germany
E-mail: dippele@klilu.de

References
1 Criscione VD WM. Incidence of cutaneous T-cell lymphoma in the United States 1973–2002. Arch Dermatol 2007; 143: 854–9.
2 Assaf CGS, Steinhoff M, Nashan D et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 2007; 5: 662–8.
3 Weinstock M. Epidemiology of mycosis fungoides. Semin Dermatol 1994: 154–9.
4 Sz Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten. AWMF-Registernummer: 023/051OL, Version 11 – Januar 2014: AWMF, DKG.
5 Trautinger F, Eder J, Assaf C et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. Eur J Cancer 2017; 77: 57–74.
6 Swerdlow S, Campo E, Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Ed. 4th revised Ed. Edition. World Health Organization, 2017.
7 Willemsen R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703–14.
8 Elder D, Massi D, Scolyer R, Willemsen R. WHO Classification of Skin Tumours. 4th edn. International Agency for Research on Cancer, Lyon, France, 2018.
9 Senff NJNE, Kim YH, Bagot M et al. European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008;112: 1600–9. Blood 2008; 112: 1600–9.
10 Nicolay JP, Felcht M, Schledzewski K et al. Sézary syndrome: old enigmas, new targets. J Dtsch Dermatol Ges 2016; 14: 256–64.
11 Boonk SE, Zoutman WH, Marie-Caroline A et al. Evaluation of immunophenotypic and molecular biomarkers for Sézary syndrome using standard operating procedures: a multicenter study of 59 patients. J Invest Dermatol 2016; 136: 1564–72.
12 Klemke CD, Dippel E, Dembinski A et al. Clonal T-cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in the skin and blood of patients with parapsoriasis and early-stage mycosis fungoides. J Pathol 2002; 197: 348–54.
13 Ahuja AT, Ying M, Ho SY et al. Ultrasound of malignant cervical lymph nodes. Cancer Imaging 2008; 8: 48–56.
14 Tsai EY, Taur A, Espinosa L et al. Staging accuracy in mycosis fungoides and Sézary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006; 142: 577–84.
15 Kuo PH, McClellan BL, Carlson K et al. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol 2008; 10: 74–81.
16 Feeney J, Horwitz S, Gonen M, Schofer H. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol 2010; 195: 333–40.
17 Dan S, Qiang G, Shu-Xia W, Chang-Hong L. Preliminary discussion on the value of (18)F-FDG PET/CT in the diagnosis and early staging of non-mycosis fungoides/Sézary’s syndrome cutaneous malignant lymphomas. Eur J Radiol 2015; 84: 1293–8.
18 Olsen E, Vonderheid E, Pimpinelli N et al. ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713–22.
19 Scarisbrick JJ, Hodak E, Bagot M et al. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer 2018; 93: 47–56.
20 Kim YH, Willemze R, Pimpinelli N et al. ISCL, the E. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479–84.
21 Assaf C, Hummel M, Steinhoff M et al. Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostisch prognostisch implications. Blood 2005; 105: 503–10.
22 Fraser-Andrews EA, Mitchell T, Ferreira S et al. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and
outcome suggests prognostic relevance in mycosis fungoides. Br J Dermatol 2006; 155: 756–62.

23 Olsen EA, Hodak E, Anderson T et al. Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 2016; 74: 27–58.

24 Kamstrup MR, Lindahl LM, Gniadecki R et al. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol 2012; 166: 399–404.

25 Neelis KJ, Schimmel EC, Vermeer MH et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009; 74: 154–8.

26 Akhtari M, Reddy JP, Pinnix CC et al. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leuk Lymphoma 2016; 57: 34–8.

27 Thomas TO, Agrawal P, Guitart J et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 2013; 85: 747–53.

28 Elsayad K, Kroeger K, Greve B et al. Total skin electron beam for primary cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 2015; 93: 1077–86.

29 Lloyd S, Chen Z, Foss FM et al. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. J Am Acad Dermatol 2013; 69: 537–43.

30 Kamstrup MR, Gniadecki R, Iversen L et al. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys 2015; 92: 138–43.

31 Hoppe RT, Harrison C, Tavallae M et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 2015; 72: 286–92.

32 Elsayad K, Kroeger K, Greve B et al. Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome. Strahlenther Onkol 2020; 166: 77–84.

33 Elsayad K, Stadler R, Steinbrink K, Eich HT. Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome. J Dtsch Dermatol Ges 2020; 18: 193–97.

34 Stadler R. Optimal combination with PUVA: rationale and clinical trial update. Oncology (Williston Park) 2007; 21: 29–32.

35 Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578–81.

36 Nikolaou V, Siakantaris MP, Vassilakopoulos TP et al. PUVA plus interferon alpha2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series. J Eur Acad Dermatol Venereol 2011; 25: 354–7.

37 Duvic M, Hymes K, Heald P et al. Bexarotene Worldwide Study G. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II–III trial results. J Clin Oncol 2001; 19: 2456–71.

38 Duvic M, Martin AG, Kim Y et al. Worldwide Bexarotene Study G. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581–93.

39 Assaf C, Bagot M, Dummer R et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006; 155: 261–6.

40 Gniadecki R, Assaf C, Bagot M et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433–40.

41 Schiller M, Tsianakas A, Sterry W et al. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2017; 31: 1841–47.

42 Hüsken AC, Tsianakas A, Hensen P et al. Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2012; 26: 71–8.

43 Kim YH, Bagot M, Pinter-Brown L et al. Investigators M. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192–204.

44 Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109–15.

45 Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485–91.

46 O’Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182–9.

47 Prince HM, Duvic M, Martin A et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 1870–7.

48 Marchi E, Alinari L, Tani M et al. Gemicitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104: 2437–41.

49 Duvic M, Talpur R, Wen S et al. Phase II evaluation of gemicitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006; 7: 51–8. Blazejak C, Stranzenbach R, Gosman J, Gambichler T, Wehkamp U, Stendel S, Klemke CD, Wobser M, Olk J, Nicolay JP, Weyermann M, Stadler R, Assaf C. Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemicitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network. Dermatology. 2021 Sep 21:9.

50 Wollina U, Dummer R, Brockmeyer NH et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003; 98: 993–1001.

51 Hughes CF, Khot A, McCormack C et al. Lack of durable disease control with chemotherapy for mycosis fungoides and
Sézary syndrome: a comparative study of systemic therapy. Blood 2015; 125: 71–81.
52 Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol 2006; 16: 391–3.
53 Rook AH, Gelfand JM, Wysocka M et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood 2015; 126: 1452–61.
54 Whittaker S, Ortiz P, Dummer R et al. Efficacy and safety of bezarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB–IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCTo0056056). Br J Dermatol 2012; 167: 678–87.
55 Mehr T, Ikenberg K, Moos RM et al. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome. JAMA Dermatol 2015; 151: 73–7.
56 Kim YH, Tavallaee M, Sundram U et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable cd30 expression level: a multi-institution collaborative project. J Clin Oncol 2015; 33: 3750–8.
57 Moritz RK, Ditschkowski M, Klemke CD et al. Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T-cell lymphoma – a case series of the ADF working group “cutaneous lymphomas”. J Dtsch Dermatol Ges 2014; 12: 39–46.
58 Lechowicz Mj et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sézary syndrome. Bone Marrow Transplant 2014; 1360–5.
59 Dippel E, Schrag H, Goerdts S, Orfanos CE. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet 1997; 350: 32–3.
60 Watanabe R, Teague JE, Fisher DC et al. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythroderma as a positive predictor of complete remission. JAMA Dermatol 2014; 150: 776–9.
61 Coors EA, von den Driesch P. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and flucortolone therapy. Br J Dermatol 2000; 143: 127–31.
62 Available from: https://www.g-ba.de/informationen/be-schlussue/1951/ [Last accessed 04/10/2014].
63 Booken N, Weiss C, Utikal J et al. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome. J Dtsch Dermatol Ges 2010; 8: 428–38.
64 Bernengo MG, Quaglino P, Comessatti A et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784–94.
65 Yu JB, McNiff JM, Lund MW, Wilson LD. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys 2008; 70: 1542–5.
66 Kempf W, Pfaltz K, Vermeer MH et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024–35.
67 Fabbri A, Cencini E, Alterini R et al. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. Eur J Haematol 2014; 93: 129–36.
68 Grange F, Joly P, Barbe C et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 2014; 150: 535–41.
69 Assaf C, Gellrich S, Whittaker S et al. CD26-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol 2007; 60: 981–9.
70 Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutic approaches. Br J Haematol 2016; 174: 188–202.
71 Pemmaraju N, Lane AA, Sweet KL et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 2019; 380: 1628–37.
72 Guenova E, Schanz S, Hoetzenecker W et al. Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. Br J Dermatol 2014; 171: 891–4.
73 Willems R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111: 838–45.
74 Ohtsuka M, Miura T, Yamamoto T. Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma: a literature review of published Japanese cases. Eur J Dermatol 2017; 27: 34–41.
75 Michonneau D, Petrella T, Ortonne N et al. Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol 2017; 97: 358–64.
76 Duvic M, Tetzlaff MT, Gangar P et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 2015; 33: 3759–65.
77 Vaque JP, Gomez-Lopez G, Monsalvez V et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood 2014; 123: 2034–43.
78 Martinez-Gonzalez MC, Verea-Hernando MM, Yebra-Pimentel MT et al. Imiquimod in mycosis fungoides. Eur J Dermatol 2008; 18: 148–52.
79 Prince HM, Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin Cancer Res 2012; 18: 3509–15.
80 Sawas A, Radeski D, O’Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol 2015; 6: 202–8.
81 Querfeld C, Rosen ST, Guitart J et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 2014; 123: 1159–66.
82 Kim SJ, Yoon DH, Kang HJ et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012; 48: 3223–31.
83 Zinzani PL, Musuraca G, Tani M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293–7.
Perez C, Gonzalez-Rincon J, Onaindia A et al. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica 2015; 100: e450–3.

Scott LM, Gandhi MK. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Blood Rev 2015; 29: 405–15.

Byrd JC, Flynn JM, Kipps TJ et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 2016; 127: 79–86.

Gupta IV, Jewell RC. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B-cell hematologic malignancies. Ann N Y Acad Sci 2012; 1265: 43–56.

Fang C, Zhu D, Dong H et al. Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B-cell lymphoma: a systematic review and meta-analysis. Int J Clin Exp Med 2015; 8: 10705–13.

Boyle EM, Morschhauser F. Pixintron: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opin Drug Saf 2015; 14: 601–7.

Herbrecht R, Cernohous P, Engert A et al. Comparison of pixintrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol 2013; 24: 2618–23.

Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 2015; 125: 22–32.

Gupta E, Accurso J, Sluzevich J et al. Excellent outcome of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive highly refractory primary cutaneous diffuse large B-cell lymphoma: a non-randomised, phase 1b study. Lancet Oncol 2014; 15: 1019–26.

Sehn LH, Herrera AF, Flowers CR et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020; 38: 155–65.

Stadler R, Scarisbrick JJ. Maintenance therapy in patients with mycosis fungoides or Sezary syndrome: A neglected topic. Eur J Cancer 2021; 142: 38–47.

Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T-cell lymphoma. Int J Dermatol 2012; 51: 930–4.

Misery L. Pruritus in cutaneous T-cell lymphomas. In: Carstens E, Akiyama T: Itch: Mechanisms and Treatment. Boca Raton (FL), 2014.

Ständler S, Zeidler C, Augustin M. S3-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus. AWMF-Reg.-Nr. 013–048, Version 30/2016: AWMF, 2016.

Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006; 55: 543–4.

Davis MP, Frandsen JL, Walsh D et al. Mirtazapine for pruritus. J Pain Symptom Manage 2003; 25: 288–91.

Brune A, Metze D, Luger TA, Ständer S. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients]. Hautarzt 2004; 55: 1130–6.

Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009; 361: 1415–6.

Suga H, Sugaya M, Miyagaki T et al. Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma. Clin Cancer Res 2014; 20: 4339–48.

Wohlrab J, Staubach P, Augustin M et al. S2k guidelines for the use of topical preparations on the skin. J Dtsch Dermatol Ges 2018; 16: 376–92.

Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850–78.

Augustin M, Wilsman-Theis D, Körber A et al. Positionspapier: Diagnostik und Therapie der Xerosis cutis. J Dtsch Dermatol Ges 2018; 16 (Suppl 4): 3–35.

Beynon T, Radcliffe E, Child F et al. What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence. Br J Dermatol 2014; 170: 599–608.

Beynon T, Selman L, Radcliffe E et al. “We had to change to single beds because I itch in the night”: a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma. Br J Dermatol 2015; 173: 83–92.

Selman LE, Beynon T, Radcliffe E et al. “We’re all carrying a burden that we’re not sharing”: a qualitative study of the impact of cutaneous T-cell lymphoma on the family. Br J Dermatol 2015; 172: 1581–92.

Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphomas on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107: 2504–11.

Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. AWMF-Registernummer: 128/001-OL, Langversion 20 – August 2019: AWMF, DKG, DKH, 2019.

Servitje O, Muniesa C, Benavente Y et al. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients. J Am Acad Dermatol 2013; 69: 357–65.

Terhorst D, Mestel DS, Humme D, Sterry W, Beyer M. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas. Br J Dermatol 2012; 166: 1295–300.

Tilly H, Gomes da Silva M, Vitolo U et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl 5): v116–25.

Lin TL, Kuo MC, Shih LY et al. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol 2012; 91: 1741–5.

Hong J, Yoon HH, Ahn HK et al. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective
analysis of patients with diffuse large B-cell lymphoma. Acta Haematol 2013; 130: 305–11.

118 El-Sharkawi D, Basu S, Ocampo C et al. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. Leuk Lymphoma 2012; 53: 1949–52.

119 Mehner-Theuerkauf A, Petersen C, Koch U. Empfehlungen zur Psychoonkologischen Versorgung im Akutkrankenhaus. Zeitschrift für Medizinische Psychologie 2003; 12: 77–84.

120 Loscalzo M, Clark KL, Holland J. Successful strategies for implementing biopsychosocial screening. Psychooncology 2011; 20: 455–62.

121 Holland JC, Andersen B, Breitbart WS et al. Distress management. J Natl Compr Canc Netw 2010; 8: 448–85.

122 Bhat TS, Herbosa CM, Rosenberg AR et al. Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma. Br J Dermatol 2021; 184: 310–8.

123 Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol 2012; 67: 760–8.

124 Sampogna F, Frontani M, Baliva G et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol 2009; 160: 815–22.

125 Wright A, Wijeratne A, Hung T et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manage 2013; 45: 114–9.

126 Molloy K, Jonak C, Woei AJF et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPi) study. Br J Dermatol 2020; 182: 770–9.

127 Selman LE, Beynon T, Radcliffe E et al. “We’re all carrying a burden that we’re not sharing”: a qualitative study of the impact of cutaneous T-cell lymphoma on the family. Br J Dermatol 2015; 172: 1581–92.

128 Prince HM, Kim YH, Horwitz SM et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555–66.

129 Bagot M, Porcu P, Marie-Cardine A et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol 2019; 20: 1160–70.

130 Dummer R, Prince HM, Whittaker S et al. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer 2020; 133: 120–30.

131 Porcu P, Hudgens S, Horwitz S et al. Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk 2021; 21: 97–105.

132 Nawar T, Elsayad K, Müller EC et al. Quality of life in patients with mycosis fungoides and Sezary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapy. Acad Dermatol 2021; 50(2): 181–9.

133 Radbruch L, Caraceni A, De Vlieger T. Standards and Richtlinien für Hospiz- und Palliativversorgung in Europa: Teil 11; Weißbuch zu Empfehlungen der Europäischen Gesellschaft für Palliative Care (EAPC); White Paper on Standards and Norms for Hospice and Palliative Care in Europe: Part 1; Recommendations of the European Association for Palliative Care. Z Palliativmed 2011; 216–27.

134 Lebon B, Beynon TA, Whittaker SJ. Palliative care in patients with primary cutaneous lymphoma: symptom burden and characteristics of hospital palliative care team input. Arch Dermatol 2007; 143: 423–4.